Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage

Acta Ophthalmologica

Volumn 91, Issue 3, 2013, Pages 274-278

  Mayer, Wolfgang J ^a   Hakim, Imad ^a   Haritoglou, Christos ^a   Gandorfer, Arnd ^a   Ulbig, Michael ^a   Kampik, Anselm ^a   Wolf, Armin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AMD; avastin; bevacizumabrtPA; subretinal haemorrhage

Indexed keywords

ALTEPLASE; BEVACIZUMAB; SULFUR HEXAFLUORIDE; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL HAEMORRHAGE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CATARACT EXTRACTION; COMBINED MODALITY THERAPY; ENDOTAMPONADE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRAVITREAL INJECTIONS; MALE; PILOT PROJECTS; RECOMBINANT PROTEINS; RETINAL HEMORRHAGE; RETROSPECTIVE STUDIES; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 84876414527     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02264.x     Document Type: Article

References (18)

1. Avery RL, Fekrat S, Hawkins BS, &, Bressler NM, (1996): Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16: 183-189.
2. Bressler NM, Bressler SB, Childs AL, et al., (2004): Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 111: 1993-2006.
3. Colenbrander A, (2001): Measuring vision and vision loss.
4. Fung AE, Lalwani GA, Rosenfeld PJ, et al., (2007): An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
5. Glatt H, &, Machemer R, (1982): Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 94: 762-773.
6. Guthoff R, Guthoff T, Meigen T, &, Goebel W, (2011): Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina 31: 36-40.
7. Heriot W, (1996): Intravitreal gas and rtPA: an outpatient procedure for subretinal hemorrhage. Vail Vitrectomy Meeting, Vail, CO.
8. Hillenkamp J, Surguch V, Framme C, Gabel VP, &, Sachs HG, (2010): Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 248: 5-11.
9. Hohn F, Mirshahi A, &, Hattenbach LO, (2009): [Combined intravitreal injection of bevacizumab and SF(6) gas for treatment of submacular hemorrhage secondary to age-related macular degeneration]. Ophthalmologe 4: 328-332.
10. Hohn F, Mirshahi A, &, Hattenbach LO, (2010): [Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration]. Ophthalmologe 107: 328-332.
11. Kamei M, Misono K, &, Lewis H, (1999): A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 128: 739-746.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al., (2009): A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148: 43-58.
13. Luke M, Januschowski K, Warga M, et al., (2007): The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 91: 1077-1082.
14. Meyer CH, Scholl HP, Eter N, Helb HM, &, Holz FG, (2008): Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 86: 490-494.
15. Ohji M, Saito Y, Hayashi A, Lewis JM, &, Tano Y, (1998): Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 116: 1326-1332.
16. Sacu S, Stifter E, Vecsei-Marlovits PV, Michels S, Schutze C, Prunte C, &, Schmidt-Erfurth U, (2009): Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond) 23: 1404-1410.
17. Scupola A, Coscas G, Soubrane G, &, Balestrazzi E, (1999): Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 213: 97-102.
18. Toth CA, Morse LS, Hjelmeland LM, &, Landers MB 3rd, (1991): Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 109: 723-729.